Weight loss drugs could save airlines money on fuel as Americans shed pounds
As obesity rates among Americans drop and weight loss drugs lead to a slimmer society, airlines could save on fuel costs, according to a recent analysis.
Watch CBS News
As obesity rates among Americans drop and weight loss drugs lead to a slimmer society, airlines could save on fuel costs, according to a recent analysis.
FDA-approved semaglutide drug is the first GLP-1 pill for weight loss available in the U.S., according to drugmaker Novo Nordisk.
Experts said this time of year they see a real uptick in diets, gym memberships and even medical interventions to help people reach their goals.
The Food and Drug Administration has approved a pill version of the weight-loss drug Wegovy.
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.
WeightWatchers, founded in 1963, has struggled to shed debt and cope with the emergence of weight loss drugs.
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.
About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to several obesity experts.
Record demand for Ozempic, Wegovy and other weight loss drugs is fueling a surge of dangerous knockoffs.
Drugs like Mounjaro and Ozempic, which many use for weight loss, may also help patients suffering from addiction, according to a new study.
The latest CDC survey found 4 in 10 adults in the U.S. were obese. A map shows the states with the highest and lowest rates.
High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the meantime, a market for cheaper, compounded drugs thrives.
Do weight loss drug labels warn enough about potential side effects? A patient who needed emergency surgery is suing prescription drugmaker Novo Nordisk.
The investigation into a listeria outbreak linked to deli meats from Boar's Head continues, Eli Lilly is cutting the price of its weight loss drug Zepp and the number of "401k millionaires" is growing.
Semaglutide, the active ingredient in drugs like Wegovy and Ozempic, can help people lose weight — and a new study says it may also help people quit smoking.
Michigan's largest insurance company said it will begin eliminating coverage of various weight loss drugs next year.
GLP-1 class medications reduce cardiovascular risk and treat diabetes. But they also allow people to lose an average of 10-20 percent of their body weight in the first year. What does that mean for the overweight or obese?
Ozempic and other GLP-1 RA drugs, including Wegovy, Mounjaro and Zepbound, are being scrutinized.
From the Ozempic "ripple effect" to health tech and more, experts share their predictions for 2024 wellness trends.
The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
The warning about scams comes as sales have boomed for Ozempic, Wegovy and other drugs used for weight loss.
The FDA stopped short of saying the potentially life-threatening condition was caused by the drugs, which have become popular for weight loss.
Experts say the drugs can slow digestion so much that it puts patients at increased risk for a problem called pulmonary aspiration, which can cause dangerous lung damage, infections and even death.
A personal injury law firm filed a suit against Novo Nordisk and Eli Lilly and Co., the manufacturers of Ozempic and Mounjaro.
